Evidence map›Paper›PMID 28931089›Full record

Trial reportPloS one2017

Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial.

Rabi Yacoub, Melinda Nugent, Weijin Cai, Girish N Nadkarni, Lee D Chaves, Sham Abyad, Amanda M Honan, Shruthi A Thomas, Wei Zheng, Sujith A Valiyaparambil and 7 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 2 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Gut-kidney axis: Dysbiosis and renal disease.World journal of nephrology · 2026
    Review
  7. Dietary Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic Complications.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Rabi YacoubDepartment of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.ORCID http://orcid.org/0000-0002-0479-4667
Melinda NugentDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Weijin CaiDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Girish N NadkarniDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Lee D ChavesDepartment of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
Sham AbyadDepartment of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
Amanda M HonanDepartment of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
Shruthi A ThomasDepartment of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
Wei ZhengDepartment of Computer Science and Engineering, University at Buffalo, Buffalo, New York, United States of America.
Sujith A ValiyaparambilDepartment of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
Mark A BryniarskiDepartment of Phamaceutical Sciences, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, United States of America.
Yijun SunDepartment of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
Michael BuckDepartment of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
Robert J GencoDepartment of Oral Biology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
Richard J QuiggDepartment of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
John C HeDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Jaime UribarriDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
University at Buffalo, State University of New York · USIcahn School of Medicine at Mount Sinai · US

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Oral Microbiome and Periodontitis: A Prospective Study in Postmenopausal WomenR01DE024523 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI WACTAWSKI-WENDE, JEAN · 2014 to 2018
$3.8M
Cellular and molecular mechanisms of retinoids in podocytesR01DK078897 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HE, JOHN CIJIANG · 2007 to 2018
$3.6M
Developing Advanced Algorithms to Address Major Computational Challenges in Current Microbiome ResearchR01AI125982 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI SUN, YIJUN · 2016 to 2018
$973k
Risk Clustering and Stratification in Genetically High-Risk Individuals Using Electronic Medical Records and BiomarkersK23DK107908 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI NADKARNI, GIRISH NITIN · 2016 to 2020
$930k
BLRD VA I01 BX000345NCATS NIH HHS UL1 TR001412NIAID NIH HHS R01 AI125982NIDCR NIH HHS R01 DE024523NIDDK NIH HHS K23 DK107908NIDDK NIH HHS R01 DK078897
6 · The paper itself

Abstract

The modern Western diet is rich in advanced glycation end products (AGEs). We have previously shown an association between dietary AGEs and markers of inflammation and oxidative stress in a population of end stage renal disease (ESRD) patients undergoing peritoneal dialysis (PD). In the current pilot study we explored the effects of dietary AGEs on the gut bacterial microbiota composition in similar patients. AGEs play an important role in the development and progression of cardiovascular (CVD) disease. Plasma concentrations of different bacterial products have been shown to predict the risk of incident major adverse CVD events independently of traditional CVD risk factors, and experimental animal models indicates a possible role AGEs might have on the gut microbiota population. In this pilot randomized open label controlled trial, twenty PD patients habitually consuming a high AGE diet were recruited and randomized into either continuing the same diet (HAGE, n = 10) or a one-month dietary AGE restriction (LAGE, n = 10). Blood and stool samples were collected at baseline and after intervention. Variable regions V3-V4 of 16s rDNA were sequenced and taxa was identified on the phyla, genus, and species levels. Dietary AGE restriction resulted in a significant decrease in serum Nε-(carboxymethyl) lysine (CML) and methylglyoxal-derivatives (MG). At baseline, our total cohort exhibited a lower relative abundance of Bacteroides and Alistipes genus and a higher abundance of Prevotella genus when compared to the published data of healthy population. Dietary AGE restriction altered the bacterial gut microbiota with a significant reduction in Prevotella copri and Bifidobacterium animalis relative abundance and increased Alistipes indistinctus, Clostridium citroniae, Clostridium hathewayi, and Ruminococcus gauvreauii relative abundance. We show in this pilot study significant microbiota differences in peritoneal dialysis patients' population, as well as the effects of dietary AGEs on gut microbiota, which might play a role in the increased cardiovascular events in this population and warrants further studies.

Indexed as

Cardiovascular DiseasesDietFecesFemaleGastrointestinal MicrobiomeGlycation End Products, AdvancedHumansKidney Failure, ChronicMaleMiddle AgedPeritoneal DialysisPilot ProjectsGlycation End Products, Advanced

Identifiers

PMID28931089
PMCPMC5607175
OpenAlexW2754799198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.